Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Other hematologic neoplasm 7Plasma cell 1CNS 1Breast 1

Conditions

Multiple Myeloma 1Hematologic Diseases 1

Interventions

Dexamethasone 47Lenalidomide 31daratumumab 24Bortezomib 23pomalidomide 19carfilzomib 15Specimen Handling 15Cyclophosphamide 15Calcium Dobesilate 15Biopsy 15Magnetic Resonance Spectroscopy 11talquetamab 9isatuximab 9Melphalan 9iberdomide 8dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8fludarabine 7belantamab mafodotin 7selinexor 5X-Rays 5tocilizumab 4fludarabine phosphate 4elotuzumab 4Nuclear Medicine Department, Hospital 4trametinib 3dabrafenib 3Whole-Body Irradiation 3Thalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukapheresis × Plasma cell × 30 days × Clear all
NCT05032820 2026-05-19

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Medical College of Wisconsin

Phase 2 Completed
40 enrolled 32 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡